Venus Medtech (hangzhou), Inc. Class H · HKEX:2500
Venus Medtech (hangzhou), Inc. Class H — H1 2025 Earnings Presentation
26 slides from Venus Medtech (hangzhou), Inc. Class H's earnings presentation, Sep 5, 2025
Slide 1: Venusmedtech 2025 Interim Performance
Be a) ISA fT ARSE UBS 2500.HK =H Fah 2025 + PP BA Mb 2h Venusmedtech 2025 Interim Performance 20259A
Slide 2: ai paaA lesee
ai paaA lesee Vay, \VENUSMEDTECH BISMOSARRTHAD, RETARRTMA, ATARRUTRHAR: ARATHAPRHRNSHETEARA RRA] (GM AAS] “) ERABAMPHRTMER, SERS. RANMA RTM RENE AL) AERA RE NBME KE. EPMAMANAM EES REIS SRO ATE. HERRTE. TORETESR ETE EMRE RAR RIE, EMA MRM RMAME BANE. AIPA AES. WS. SAR. AtkA. BR. WRAL, RBA, MARR, WAAAR
Slide 3: CONTENTS
CONTENTS Am @ Fetes VENUSMEDTECH PART 01 PART 02 PART 03 2025 SF PRAM 55 bs ATW ei malktt RAB) ALAS I ARIE FR RM SRM pace 03
Slide 4: Part 01
VENUSMEDTECH PART 01 20255¢ PRAM SS HA ba Be 23 a) ARB
Slide 5: 2025 interim business highlights
20255 PRAM 35 BE aeeIT RAPER IE His UN AS ERT ACG a OS Ee 7h 5S BSA) OUT AETT 2025 LF Si B4 23504 SRSA TA PPRDABMA, H4smsHLEeRE Eh SONKAA,OTZATCARIB, [ILI K35.5% SARGEAR WSINKA HbA B21.8%, SHIRL AITTOT MNCHKARCardiovalveH BHAA) “ATRIA” BSA = 22918 HHA GCardiovalve Target BRINKS EIR BS AB Rit ARERR,
Slide 6: Upcoming milestones
ARIZTAL 2B] EYES Bee ® F) @ RAM E HR BIOMS . = EATER ULLa + AE am FRR HA Eth IH SAO + BBS) RAIS PBL aol AL PUES AAR es , . @ KAA PIRATE APRREPEM IME OE REI RE ° FRCS hate, AAAS A, BEEN Spich PESTA RIES BPA LEGALS | RINE + Venus-PowerX: 2026H13EAK RAL . SURFS. WEoNTE + VenusP-Valve: 2026H152nx: DEI A
Slide 7: Part 02
VENUSMEDTECH PART 02 == (AIF oo Be 29 128 Balls REE Fe
Slide 8: Product portfolio
=n Ge ) ° ° ° ° ° ° ° ° VenusA-Valve VenusA-Plus VenusA-Pro VenusA-Deluxe Venus-PowerX Venus-Vitae VenusP-Valve Cardiovalve Cardiovalve G Sheath TAVO eter \VENUSMEDTECH Shek @ THER IRD IARI oS Eat Ei BERS, GA, MPM EBL NARA BTHE, SRS, CMSnSHaRit BFhE, BA, MPM, EBL VARIA BF PRR FREGAAABTH PARE SAE FRE
Slide 9: Product pipeline and progress
BE oD AML SMR LA 4+ PF aaiait 20285 FRAT IRHL EMER Us RBA ESE mlktt ARitip =RMLE RM BHR Cardiovalve + SRM CER RTE MA RAE 1406), FIt2025 EE BOSE BUI A aH 3eCEEM Ria TAM BRA AE ls RE Bama ESRB RAMT2027H1 BSR e=e foBRES7 \VENUSMEDTECH Hib oh RK HR BS Bt rim aiR VenusP-Valve + 20224545 BRANCE MDR3RIL; 2
Slide 10: VenusA-Valve market performance
VenusAAII* mihi EFInETERA, EES SAU BEA ei ae \VENUSMEDTECH VenusA-Valve: BIAIE——RAB 105 1HAM IDeA RA TAVRE Ga os MCE 10000% ARLESAECR ARLES am ke » 61.39% 17.8% _ go%o KL KESERREIS, FLAICERUSLEMRR EH BAGS seam Shame 60.00% RKMARE TRAE 62 5° 42.57% ainaled “0 33.66% 40.00% 43 30 30.00% 20 20.00% 9.90
Slide 11: VenusA-Plus clinical results
VenusAR9I = miffike Fir VenusA-Plus PES 5) EUR TAVR aa ER EAR Et SSA BE eter \VENUSMEDTECH By ia] 30% 2art AUB BORE kA Ree aHE FR PRM 3 (4.8%) 1 128 5 (8%) 1 2 2% 9 (14.5%) 12 (19.4%) 14 (22.6%) 18 (29%) 1 2 3% 1 2 1 2 ae 5 1 2 w REVHREERARE, SARS VenusA-Plus 5Fh@isstig AR WEL ESL 83.3% 90.3% 8B SAA
Slide 12: Venus-PowerX clinical data
Venus-PowerX #4 HAR) {st ERAN aOR iy 2025431, Venus-PowerX HAA (THHAR (REDD AS) WSR, REMAMIMPERS ARE 1Year Venus-PowerXWFABRET Variables (n= 25) - + BARA RIALO0% VARC-3 device success 22 (88.0) « SRAVATHRALIE100% (25/256) & netseiorAL Me) uo) + 2G) 82 DR RLE ERI PSL 100%R2 BE Vnax23 m/s or mean grad
Slide 13: Cardiovalve clinical data
Cardiovalve: BRhiyy3 aenes7 > 206i Sichal Gere ‘SAGE (N=56) RIFE HHS Ry RE 12TANYHAD RES 1% 2% 2% TR at BL (N=125) TR at 30D (N=100) TR at 6M (N=77) TR at 12M (N=54) Rat 2Y (N=21) NYHA at BL TRat 12M Be 30K 6tA Le 2 pace 13
Slide 14: = it BRIT 2027 EH
= it BRIT 2027 EH IRs ERM CER SO Ci 4 foBRES7 MEDTECH SAMIR (SIT ECACERH LT) FUT 2025 TEAK 1SO GI BEA Lm PI THA Pisa Pit 12-18 SAAR SRA BIR ($17t3= BF DAR Lib) BSXBFDARA TERRA AMR RAPER (S43S BRM CERH Eri) CIARA BE 8 HIFAH AR TN BEE IRDA CE FB] ah pace 14
Slide 15: SRE AA MM RB IAM @ 2882
SRE AA MM RB IAM @ 2882 WE2025F6H, AUHiHFASBMERMRERAHNST), BAH. RE. MASHR, BMIsanngHAeAl KAMLSA (Ri) RASA (A) SMR (FAB) san. y SAME = * BRE “i 898u ”" 1135 1a 345 VENUSMEDTECH pace 15
Slide 16: Cardiovalve patent litigation
FIA MEARFP, CardiovalveX# FF Br ae 202527A 16H, MB APEPEMENRAL SEs SNSREUBRER, RHEE LIAB (CAFC) ERE BEE OAS $tytCardiovalveS Af@ECHI LIF (Case: 23-1515) WRATS, AHSASAAISSABHSLAREAS (PTAB) F202212A RYH A FCardiovalveh RARE 202146848 BB+ mS ybikCardiovalve PANRESA “ARR A” Heat, Beas SEALOPRBRE 5 RRB H
Slide 17: Part 03
| 4 PART 03 UCR S RM
Slide 18: 2025 interim financial highlights
\VENUSMEDTECH 2025 PRB AMLS ennery INS Abs b+eeASY eo hig7@ L+FeABAN Ms 19508 4008 SiktteAsY Zr EreaMaY DET aNS c—J i—J TOOK 180% TARAS BL gas (OP suns 165 A SLFEWGM. AFR. Aba. USE pace 18
Slide 19: VenusP-Valve revenue
PWSSERMNSRHR, MRAM aOR iy EAVenusP-Valve79 = BY 9h Ai RI RWB RBI, XbA x EVenusP-Valve BREdRHLR, AEE IC 34.5% 18.7% bye bul PAR aang RTE Sued 2022H1 2023H1 : ; 2024H1 aw 2025H1 a
Slide 20: Revenue by product
20252 HHA A RM Bh > sao ny >s 33H 2024 1H 16.6% +. 0.1% 83.3% BTAVR «BTPVR ERR 2024 1H ‘at: ARMEAR » 87.0% 200.6 SEPA SNA eter VENUSMEDTECH 2025 1H 23.0% -——» . 0.0% | 77.0% STAR BTR ERR, 2025 LH oe: suns SONA att bE 21.8% +. 21.8% 40.7 » 78.2% 146.4 mPOA NA pace 20
Slide 21: Gross profit and expenses
PREHBERE, REGRESS alae EAA 2024 1H 2024 1H 2024 1H 180.8 33.1% 56.8% 18.4% 120.9 2025 1H 2025 1H 2025 1H 29.3% 53.7% 64.6% Ge Gene PUN S f “ei: ARBAAR GB HARA aN ss “ai: AREA ae FARA CEN SF “ef: ARMADA 202525 LAE AB) ist — 5 RAVER AS LIE HELL 20258 LH AS) MIRE SRA 202587 b HA LR Bul SEH A RES SMR A
Slide 22: Loss and EBITDA
2025SF PHAR WL F/EBITDA SH 45HRM eae Ge iia]* ae aL Pika 16.2% Sl: ARBEAR 2025 LSERFRATIAME MIS, BS em BAAMTHERIARR AEN $8, PLACATE BRE ERE: 1. LCA EA A RAR. 2. EBITDA ARITA. BUR, HTB RPA ARH rs Ei at A EBITDA* 5th 25.1H “ei: ARTEAR 2025 bE FEBITDAS RAGA ERA A EME 43.5%, 4630057ARM, REH8,20057 ARM r
Slide 23: Cash and liquidity
ART Ase ith FEAL 202547 RATT RTE RE SUZARH MEANS THE RURAA THA a WiAFE AGATE) SERLAN mike CardiovalveH EATER RHE aR She FFAS eter \VENUSMEDTECH RB HOLS eR he aa BPRWALRARS ASRS EAR BUD SAS AHS A Ml SS PAGE 23
Slide 24: Appendix
Mise SIR 4.
Slide 25: Financial statements
20252F AAA ara fi faz Fig FAR WO, wees ER) ENE FE HERDS Rams TBS AAS ma SAP RSE’ (Mi) eR RADAR ELSM KAR SELS A MSR PRB MAS 2025 H1 2024 H1 187,137 230,720 -49,149 -48,960 137,988 181,760 73.1% 78.8% 31,601 20,176 -100,459 -130,989 -120,928 -180,834 54,785 -76,575 -23,782 “17,437 “7,172 -9,805 1,238
Slide 26: Thanks
@ ISA fT HESR(8IB 2500.HK THANKS iat 20259A
Venus Medtech (Hangzhou) — H1 2025 Earnings Presentation on 6ix